utrient-gene interaction in human obesity: implications for dietary guidelines
- Conditions
- Nutritional, Metabolic, EndocrineObesity
- Registration Number
- ISRCTN25867281
- Lead Sponsor
- European Commission, Research Directorate-General (Belgium)
- Brief Summary
2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16871334 results 2012 Results article in http://www.ncbi.nlm.nih.gov/pubmed/22952648 results
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 755
1. Body mass index (BMI) =30
2. White European (by self report)
3. Age 20-50 years
4. Pre-menopausal (women)
1. Drug-treated hypertension
2. Drug-treated diabetes
3. Drug-treated hyperlipidaemia
4. Drug-treated thyroid disease
5. Use of anorexigenic agents
6. Anti-epileptic drugs
7. Anti-Parkinsonian drugs
8. Use of barbituates, benzodiasapines, beta-blockers, butyrophenones, carbonic anhydrase inhibitors, diuretics, dopamine reuptake inhibitors, digoxin, fibrates, fish oil supplement, glucocorticoids, immunosuppressives, insulin , laxatives, monoamine oxidase (MAO) inhibitors, niacin (>150 mg per day), nicotine, oral hypoglycemics, orlistat, phenothiazines, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, statins, thyroid hormone, triamterene, tricyclic antidepressants, warfarin or zonisamide
9. Surgically-treated obesity
10. Participation in ongoing drug trials
11. Pregnant women
12. Alcohol or drug abuse
13. Weight change of >3 kg within 3 months prior to clinical investigation day
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Weight loss
- Secondary Outcome Measures
Name Time Method <br> 1. Changes in waist circumference<br> 2. Body composition assessed by bio-impedance<br> 3. Fasting blood lipids<br> 4. Insulin and glucose<br>